First New Chemical Entity (NCE) approved for PD patients with motor fluctuations in the U.S.A. in over a decade 24 March 2017
Intervista a Giorgio Calderari, Helsinn Group General Manager, HC&LS Review Switzerland 20 February 2017
Linkedin